Mereo BioPharma (MREO) Operating Expenses (2023 - 2026)

Mereo BioPharma (MREO) has reported Operating Expenses for 4 consecutive years, with $7.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses fell 35.31% year-over-year to $7.0 million in Q2 2026; TTM through Jun 2026 was $34.5 million, a 26.15% decrease from a year earlier, with the FY2025 full-year figure at $40.8 million, down 13.91% from the prior year.
• Operating Expenses was $7.0 million for Q2 2026 at Mereo BioPharma, down from $8.8 million in the prior quarter.
• Over five years, Operating Expenses peaked at $15.3 million in Q4 2024 and troughed at $6.4 million in Q2 2023.
• A 4-year average of $10.0 million and a median of $9.6 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 100.81% in 2024 and sank 45.07% in 2025, its largest moves.
• Over 4 years, Operating Expenses stood at $8.4 million in 2023, then surged by 81.82% to $15.3 million in 2024, then tumbled by 45.07% to $8.4 million in 2025, then dropped by 16.21% to $7.0 million in 2026.
• The last three Operating Expenses figures came in at $7.0 million (Q2 2026), $8.8 million (Q1 2026), and $8.4 million (Q4 2025), per Business Quant data.